[1] Kurz CL,Ewbank JJ.Caenorhabditis elegans:an emerging genetic model for the study of innate immunity[J].Nat Rev Genet,2003,4(5):380-390.
[2] Tampakakis E,Okoli I,Mylonakis E.A C.elegans-based,whole animal,in vivo screen for the identification of antifungal compounds[J].Nat Protoc,2008,3(12):1925-1931.
[3] Anastassopoulou CG,Fuchs BB,Mylonakis E.Caenorhabditis elegans-based model systems for antifungal drug discovery[J].Curr Pharm Des,2011,17(13):1225-1233.
[4] Tuck S.The control of cell growth and body size in Caenorhabditis elegans[J].Exp Cell Res,2014,321(1):71-76.
[5] Weber K,Schulz B,Ruhnke M.The quorum-sensing molecule E,E-farnesol--its variable secretion and its impact on the growth and metabolism of Candida species[J].Yeast,2010,27(9):727-739.
[6] Jabra-Rizk MA,Shirtliff M,James C,et al.Effect of farnesol on Candida dubliniensis biofilm formation and fluconazole resistance[J].FEMS Yeast Res,2006,6(7):1063-1073.
[7] Shirtliff ME,Krom BP,Meijering RA,et al.Farnesol-Induced Apoptosis in Candida albicans[J].Antimicrob Agents Chemother,2009,53(6):2392-2401.
[8] Arvanitis M,Glavis-Bloom J,Mylonakis E.C.elegans for anti-infective discovery[J].Curr Opin Pharmacol,2013,13(5):769-774.
[9] Navarathna DH,Hornby JM,Hoerrmann N,et al.Enhanced pathogenicity of Candida albicans pre-treated with subinhibitory concentrations of fluconazole in a mouse model of disseminated candidiasis[J].J Antimicrob Chemother,2005,56(6):1156-1159.
[10] Navarathna DH,Hornby JM,Krishnan N,et al.Effect of farnesol on a mouse model of systemic candidiasis,determined by use of a DPP3 knockout mutant of Candida albicans[J].Infect Immun,2007,75(4):1609-1618. |